Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9140978 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL4354065 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL9142379 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL3499793 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL9141366 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL9142236 | 0.88 | TSHR (0.64) | TSHRALDH1A1TRPA1 | |
| SCHEMBL6713942 | 0.84 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL26086841 | 0.84 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL6713936 | 0.84 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL5695935 | 0.83 | TSHR (0.56) | TSHRALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117263781-A | Compound, liquid crystal composition and liquid crystal display element | 捷恩智株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20150240161-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-0670322-B1 | A silacyclohexane compound, a method of preparing it and a liquid crystal composition containing it | SHINETSU CHEMICAL CO (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | TSHR 3008/4885ALDH1A1 943/4885TRPA1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.